Natco Pharma has reported results for the fourth quarter (Q4FY26) and year ended 31st March, 2026

The company has reported 51.04% drop in its net profit at Rs 209.60 crore for the fourth quarter ended 31st March, 2026 as compared to Rs 428.10 crore for the same quarter in the previous year. The total income of the company has decreased by 44.10% at Rs 681.70 crore for Q4FY26 as compared to Rs 1,219.50 crore for the corresponding quarter previous year. On consolidated basis, the company has reported 34.11% fall in its net profit at Rs 267.90 crore for the fourth quarter ended 31st March, 2026 as compared to Rs 406.60 crore for the same quarter in the previous year. The total income of the company decreased by 36.54% at Rs 816.90 crore for Q4FY26 as compared to Rs 1,287.30 crore for the corresponding quarter previous year. For the year ended 31st March, 2026, the company has reported 30.74% fall in its net profit at Rs 1,281.50 crore as compared to Rs 1,850.40 crore for the previous year. The total income of the company has decreased by 12.23% at Rs 3,875.70 crore for year under review as compared to Rs 4,415.80 crore for year ended 31st March, 2025. For the year ended 31st March, 2026, on the consolidated basis, the company has reported 24.76% fall in its net profit at Rs 1,418.50 crore as compared to Rs 1,885.40 crore for the previous year. The total income of the company decreased by 8.53% at Rs 4,375.90 crore for year under review as compared to Rs 4,784.00 crore for year ended 31st March, 2025. $NATCOPHARM